L’accesso ai farmaci per malattie rare tra aspetti regolatori e priorità di salute pubblica
Enrico Costa(Brigham and Women's Hospital), Armando A. Genazzani(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Vittorio Del Grosso(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Grimaldi(Italian Medicines Agency), Antonella Isgrò(Italian Medicines Agency)
Cited by 1
Related Papers
Outrageous prices of orphan drugs: a call for collaboration
|The Lancet|2018|160
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
|Orphanet Journal of Rare Diseases|2022|51
Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysis
|Cancer Treatment Reviews|2015|45
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (<scp>HASTE</scp>): How to meet major health needs at a reasonable cost
|American Journal of Hematology|2020|31
Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury
|European Journal of Internal Medicine|2020|22